Rallybio drops drug for rare maternal disorder following Phase II fail
US-based biotech Rallybio is ending its RLYB212 programme for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) following disappointing…
Hematological Disorders
-
-
Novartis reports topline outcomes from Phase IIIB PNH trial of Fabhalta
Novartis has reported positive topline outcomes from the multicentre Phase IIIB APPULSE-PNH trial of oral Fabhalta (iptacopan) for treating adults…
-
Johnson & Johnson’s CARVYKTI improves survival in multiple myeloma trial
Johnson & Johnson has reported data from the Phase III CARTITUDE-4 clinical trial where CARVYKTI (ciltacabtagene autoleucel), its cell therapy,…
-
Enliven Therapeutics’ ELVN-001 shows promise in Phase I CML trial
Enliven Therapeutics has reported the latest positive results from the Phase I clinical trial showing promise of ELVN-001 for treating…
-
BMS and 2seventy bio to discontinue enrolment in multiple myeloma trial
Bristol Myers Squibb (BMS) and 2seventy bio have announced plans to discontinue enrolment of subjects in the Phase III KarMMa-9…
-
Actinium Pharmaceuticals reports data from Phase III trial of AML treatment
Actinium Pharmaceuticals has reported data from the Phase III SIERRA clinical trial of Iomab-B (Iodine-131-apamistamab) to treat patients with relapsed…
-
Rigel enrols first participant in Phase Ib/II AML treatment regimen trial
Rigel Pharmaceuticals has announced the enrolment of the first subject in a Phase Ib/II clinical trial of REZLIDHIA (olutasidenib) in…
-
MSD commences Phase III trial of thrombocythemia treatment
MSD (Merck & Co.) has announced the commencement of the Phase III Shorespan-007 clinical trial of bomedemstat (MK-3543), an investigational…
-
Opna Bio doses first subject in Phase I trial of treatment for multiple myeloma
Swiss biopharmaceutical company Opna Bio has dosed the first subject in a Phase I clinical trial of OPN-6602, an EP300/CBP…
-
Ascentage Pharma receives approval for myelodysplastic syndrome treatment trial
China-based pharmaceutical company Ascentage Pharma has received approval for a Phase III clinical trial of lisaftoclax (APG-2575) to treat newly…
